Abstract
The goal of treating hypertension in patients with diabetes is reduction of macrovascular and microvascular complications. Most current guidelines recommend more aggressive treatment goals with blood pressure (BP) targets of < 130/80 mmHg. Retrospective data analyses suggest an association between a lower BP and slower declines in chronic kidney disease (CKD) as well as greater cardiovascular (CV) risk reduction in patients with type 2 diabetes. Such recommendations, however, are not supported by appropriately powered prospective outcome trials. Indeed, several important questions regarding aggressive lowering of BP levels are still unanswered. Major limitations of most existing clinical trials of BP lowering in diabetes is the failure to either target or achieve mean systolic BP values below 130 mmHg. Data from more recent randomized trials that evaluated different levels of BP do not support a BP below 130/80 mmHg as providing further CV risk reduction and compared to levels below 140/90 mmHg. One consistent benefit of a lower BP level, however, is on reduction of cerebrovascular events. There is reasonable evidence that a lower BP level does further slow progression of advanced proteinuric kidney disease such that a BP goal < 130/80 mmHg is defensible. This review examines the data for and against aggressive BP lowering in patients with diabetes.
Keywords: Diabetes mellitus, blood pressure, aggressive treatment, chronic kidney disease, cardiovascular risk, hypertension, myocardial infarction, impaired fasting glucose, hazard ratio, atherosclerosis
Current Vascular Pharmacology
Title: Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes
Volume: 10 Issue: 2
Author(s): Rigas G. Kalaitzidis and George L. Bakris
Affiliation:
Keywords: Diabetes mellitus, blood pressure, aggressive treatment, chronic kidney disease, cardiovascular risk, hypertension, myocardial infarction, impaired fasting glucose, hazard ratio, atherosclerosis
Abstract: The goal of treating hypertension in patients with diabetes is reduction of macrovascular and microvascular complications. Most current guidelines recommend more aggressive treatment goals with blood pressure (BP) targets of < 130/80 mmHg. Retrospective data analyses suggest an association between a lower BP and slower declines in chronic kidney disease (CKD) as well as greater cardiovascular (CV) risk reduction in patients with type 2 diabetes. Such recommendations, however, are not supported by appropriately powered prospective outcome trials. Indeed, several important questions regarding aggressive lowering of BP levels are still unanswered. Major limitations of most existing clinical trials of BP lowering in diabetes is the failure to either target or achieve mean systolic BP values below 130 mmHg. Data from more recent randomized trials that evaluated different levels of BP do not support a BP below 130/80 mmHg as providing further CV risk reduction and compared to levels below 140/90 mmHg. One consistent benefit of a lower BP level, however, is on reduction of cerebrovascular events. There is reasonable evidence that a lower BP level does further slow progression of advanced proteinuric kidney disease such that a BP goal < 130/80 mmHg is defensible. This review examines the data for and against aggressive BP lowering in patients with diabetes.
Export Options
About this article
Cite this article as:
G. Kalaitzidis Rigas and L. Bakris George, Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes, Current Vascular Pharmacology 2012; 10 (2) . https://dx.doi.org/10.2174/157016112799304996
DOI https://dx.doi.org/10.2174/157016112799304996 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets Carbon Monoxide, A Two-Face for the Protection of the Liver
Current Pharmaceutical Biotechnology Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Presence of Distinct Virtual Backbone Torsion angles in Dipeptide Conformers
Protein & Peptide Letters Editorial [Hot Topic: Inflammation in Atherosclerosis: Current Therapeutic Approaches (Executive Guest Editor: Dimitris Tousoulis)]
Current Pharmaceutical Design Food-derived Bioactive Peptides - Opportunities for Designing Future Foods
Current Pharmaceutical Design Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery
Current Pharmaceutical Design Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Ellagic Acid Increases Osteocalcin and Alkaline Phosphatase After Tooth Extraction in Nicotinic-Treated Rats
Current Pharmaceutical Design HIV and Respiratory Disease: A Contemporary Perspective
Current Respiratory Medicine Reviews Cell Therapy for Respiratory Diseases: Optimizing Cell Delivery Strategies
Current Respiratory Medicine Reviews Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Black Widow Spider (Latrodectus mactans) Antivenom in Clinical Practice
Current Pharmaceutical Biotechnology Involvement of CYP 3A5 In the Interaction Between Tacrolimus and Nicardipine: A Case Report
Current Drug Safety Editorial [Hot Topic: Investing in Reproductive Health ]
Current Women`s Health Reviews Circulating Endothelial Progenitor Cells Biology and Regenerative Medicine in Pulmonary Vascular Diseases
Current Pharmaceutical Biotechnology Complement Activation-Related Pseudoallergy Caused by Amphiphilic Drug Carriers: The Role of Lipoproteins
Current Drug Delivery <i>Cosmos Caudatus</i>: A Possible Drug Candidate for Oral Squamous Cell Carcinoma
Current Bioactive Compounds Beneficial Effects of the Angiotensin-Converting Enzyme 2 Activator Dize in Renovascular Hypertension
Protein & Peptide Letters Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases
Current Neuropharmacology